药物-基因相互作用：药物维持剂量需求的内在变异性
Drug-gene interactions: inherent variability in drug maintenance dose requirements.
作者信息
Westervelt Paul, Cho Kihoon, Bright David R, Kisor David F
出版信息
P T. 2014 Sep;39(9):630-7.
Abstract
The influence of genetics on pharmacokinetics can introduce variability among individual patients that may cause treatment failure, toxicity, or both. Such variability, specifically in clearance rates, can influence drug maintenance dosing regimens.
摘要
遗传学对药代动力学的影响可能会在个体患者之间引入变异性，这可能导致治疗失败、毒性反应或两者皆有。这种变异性，特别是在清除率方面，会影响药物维持给药方案。
相似文献
1
2
Warfarin dosing and the promise of pharmacogenomics.华法林剂量与药物基因组学的前景。
Curr Clin Pharmacol. 2007 Jan;2(1):11-21. doi: 10.2174/157488407779422276.
3
The pharmacogenetics of immunosuppression for organ transplantation: a route to individualization of drug administration.器官移植免疫抑制的药物遗传学：实现药物个体化给药的途径。
Am J Pharmacogenomics. 2003;3(5):291-301. doi: 10.2165/00129785-200303050-00001.
4
Individual variability in clinical effect and tolerability of opioid analgesics - Importance of drug interactions and pharmacogenetics.阿片类镇痛药临床疗效和耐受性的个体差异——药物相互作用和药物遗传学的重要性。
Scand J Pain. 2017 Oct;17:193-200. doi: 10.1016/j.sjpain.2017.09.009. Epub 2017 Oct 17.
5
Validation of a proposed warfarin dosing algorithm based on the genetic make-up of Egyptian patients.验证一种基于埃及患者基因构成的华法林剂量算法。
Mol Diagn Ther. 2013 Dec;17(6):381-90. doi: 10.1007/s40291-013-0046-3.
6
Does CALU SNP rs1043550 contribute variability to therapeutic warfarin dosing requirements?CALU基因单核苷酸多态性rs1043550是否会导致华法林治疗剂量需求的变异性？
Clin Med Res. 2013 Jun;11(2):73-9. doi: 10.3121/cmr.2013.1130. Epub 2013 May 8.
7
Population-based investigations of drug relative clearance using nonlinear mixed-effect modelling from information generated during the routine clinical care of patients.利用患者常规临床护理期间产生的信息，通过非线性混合效应模型对药物相对清除率进行基于人群的调查。
J Clin Pharm Ther. 1999 Apr;24(2):103-13. doi: 10.1046/j.1365-2710.1999.00204.x.
8
The Genetics of Warfarin Dose-Response Variability in Africans: An Expert Perspective on Past, Present, and Future.非裔人群中华法林剂量反应变异性的遗传学：过去、现在和未来的专家观点。
OMICS. 2019 Mar;23(3):152-166. doi: 10.1089/omi.2019.0018.
9
The population pharmacokinetics of R- and S-warfarin: effect of genetic and clinical factors.R-和 S-华法林的群体药代动力学：遗传和临床因素的影响。
Br J Clin Pharmacol. 2012 Jan;73(1):66-76. doi: 10.1111/j.1365-2125.2011.04051.x.
10
Linearity and stability of intravenous busulfan pharmacokinetics and the role of glutathione in busulfan elimination.静脉注射白消安药代动力学的线性和稳定性，以及谷胱甘肽在白消安消除中的作用。
Biol Blood Marrow Transplant. 2011 Jan;17(1):117-23. doi: 10.1016/j.bbmt.2010.06.017. Epub 2010 Jun 30.
引用本文的文献
1
The Prevalence of Potential Drug-Drug-Gene Interactions: A Descriptive Study Using Swiss Claims Data.潜在药物-药物-基因相互作用的患病率：一项使用瑞士索赔数据的描述性研究。
Pharmgenomics Pers Med. 2025 Aug 23;18:197-208. doi: 10.2147/PGPM.S527556. eCollection 2025.
2
Utilisation of drugs with pharmacogenetic recommendations in children in Switzerland.瑞士儿童使用具有药物遗传学推荐的药物情况。
Pharmacogenomics J. 2025 Jul 11;25(4):19. doi: 10.1038/s41397-025-00378-x.
3
The impact of , , and polymorphisms on warfarin dose requirement in Saudi patients.[基因名称1]、[基因名称2]和[基因名称3]多态性对沙特患者华法林剂量需求的影响。
Front Pharmacol. 2025 Apr 30;16:1547142. doi: 10.3389/fphar.2025.1547142. eCollection 2025.
4
Pharmacogenetic Testing in the Outpatient Setting in Switzerland: A Descriptive Study Using Swiss Claims Data.瑞士门诊环境中的药物遗传学检测：一项使用瑞士医保数据的描述性研究
Drug Saf. 2025 Jun;48(6):689-696. doi: 10.1007/s40264-025-01522-z. Epub 2025 Feb 20.
5
Risk of major adverse cardiovascular events in CYP2C19 LoF genotype guided clopidogrel against alternative antiplatelets for CAD patients undergoing PCI: Meta-analysis.CYP2C19功能缺失基因型指导下的氯吡格雷与其他抗血小板药物用于接受经皮冠状动脉介入治疗的冠心病患者时发生主要不良心血管事件的风险：荟萃分析
Clin Transl Sci. 2025 Feb;18(2):e70080. doi: 10.1111/cts.70080.
6
Genetic ancestry in population pharmacogenomics unravels distinct geographical patterns related to drug toxicity.群体药物基因组学中的遗传血统揭示了与药物毒性相关的不同地理模式。
iScience. 2024 Sep 10;27(10):110916. doi: 10.1016/j.isci.2024.110916. eCollection 2024 Oct 18.
7
Exploiting meta-analysis of genome-wide interaction with serum 25-hydroxyvitamin D to identify novel genetic loci associated with pulmonary function.利用全基因组与血清25-羟维生素D相互作用的荟萃分析来鉴定与肺功能相关的新基因位点。
Am J Clin Nutr. 2024 May;119(5):1227-1237. doi: 10.1016/j.ajcnut.2024.03.007. Epub 2024 Mar 12.
8
Insight into Risk Factors, Pharmacogenetics/Genomics, and Management of Adverse Drug Reactions in Elderly: A Narrative Review.老年人药物不良反应的风险因素、药物遗传学/基因组学及管理的深入探讨：一项叙述性综述
Pharmaceuticals (Basel). 2023 Nov 1;16(11):1542. doi: 10.3390/ph16111542.
9
Effects of intermittent fasting on the histology and mRNA expression of major drug-metabolizing cyp450s in the liver of diabetic mice.间歇性禁食对糖尿病小鼠肝脏中主要药物代谢 CYP450s 的组织学和 mRNA 表达的影响。
Libyan J Med. 2023 Dec;18(1):2270188. doi: 10.1080/19932820.2023.2270188. Epub 2023 Oct 26.
10
Utilization of Drugs with Pharmacogenetic Dosing Recommendations in Switzerland: A Descriptive Study Using the Helsana Database.瑞士具有药物基因组学给药建议的药物使用情况：一项使用 Helsana 数据库的描述性研究
Pharmgenomics Pers Med. 2022 Nov 23;15:967-976. doi: 10.2147/PGPM.S382214. eCollection 2022.
本文引用的文献
1
Implementation of a pharmacogenomics service in a community pharmacy.在社区药房实施药物基因组学服务。
J Am Pharm Assoc (2003). 2014 Mar-Apr;54(2):172-80. doi: 10.1331/JAPhA.2014.13033.
2
Pharmacogenetics in the Community Pharmacy: Thienopyridine Selection Post-Coronary Artery Stent Placement.社区药房中的药物遗传学：冠状动脉支架置入术后噻吩并吡啶类药物的选择
J Pharm Pract. 2014 Aug;27(4):416-9. doi: 10.1177/0897190014522496. Epub 2014 Feb 13.
3
Polymorphic cytochrome P450 enzymes (CYPs) and their role in personalized therapy.多态性细胞色素P450酶（CYPs）及其在个性化治疗中的作用。
PLoS One. 2013 Dec 10;8(12):e82562. doi: 10.1371/journal.pone.0082562. eCollection 2013.
4
A randomized trial of genotype-guided dosing of warfarin.华法林基因指导剂量的随机试验。
N Engl J Med. 2013 Dec 12;369(24):2294-303. doi: 10.1056/NEJMoa1311386. Epub 2013 Nov 19.
5
A pharmacogenetic versus a clinical algorithm for warfarin dosing.基于药理学的华法林剂量调整算法与临床算法的比较。
N Engl J Med. 2013 Dec 12;369(24):2283-93. doi: 10.1056/NEJMoa1310669. Epub 2013 Nov 19.
6
Clinical Pharmacogenetics Implementation Consortium guidelines for CYP2C19 genotype and clopidogrel therapy: 2013 update.临床药物遗传学实施联盟 CYP2C19 基因型和氯吡格雷治疗指南：2013 年更新。
Clin Pharmacol Ther. 2013 Sep;94(3):317-23. doi: 10.1038/clpt.2013.105. Epub 2013 May 22.
7
A meta-analysis of CYP2D6 metabolizer phenotype and metoprolol pharmacokinetics.CYP2D6 代谢表型与美托洛尔药代动力学的荟萃分析。
Clin Pharmacol Ther. 2013 Sep;94(3):394-9. doi: 10.1038/clpt.2013.96. Epub 2013 May 9.
8
Association of CYP2C9 polymorphisms with phenytoin toxicity in Indian patients.CYP2C9 多态性与印度患者苯妥英钠中毒的关联。
Neurol India. 2012 Nov-Dec;60(6):577-80. doi: 10.4103/0028-3886.105189.
9
Vanderbilt pioneers bedside genetics.范德比尔特开创床边遗传学。
Biotechnol Healthc. 2012 Summer;9(2):31-2.
10
Evaluation of six proton pump inhibitors as inhibitors of various human cytochromes P450: focus on cytochrome P450 2C19.评价六种质子泵抑制剂对各种人细胞色素 P450 的抑制作用：重点关注细胞色素 P450 2C19。
Drug Metab Dispos. 2012 Sep;40(9):1698-711. doi: 10.1124/dmd.112.045575. Epub 2012 May 30.
Zotero 插件